Alector
Overview
Alector is a clinical-stage biopharmaceutical company developing immunotherapies targeting neuroinflammation and neurodegenerative diseases. The company focuses on leveraging immune biology to address underlying pathological mechanisms in conditions such as Alzheimer's disease and other neurological disorders.
More in Neurotechnology
Latest industry news
ABILITY NeuroTech Reaches First-in-Human Milestone With Novel Brain-Computer Interface
2026-07-30 · Product
Aurenar Raises $5.7M to Push Stroke Neuromodulation Device Toward Market
2026-07-29 · Funding
Neuvotion Brings Brain-Computer and Brain-Body Interface Technologies to Market as Nature Medicine Study Lands
2026-07-28 · Product
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-07-27 · Policy
Company details
Category
🏢 Neurotechnology
Funding
Private
Listed
2026-07-29
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →